

II. REMARKS**Response to Restriction Requirement**

In the Office Action, the Examiner issued a Restriction Requirement, and stated that restriction to one of the following inventions is required:

Group I: Claims 1-9 drawn to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic comprising combining an orally active opioid agonist together with naltrexone, classified in class 514, subclasses 282, 289 and 810.

Group II: Claims 12-23 drawn to an oral dosage form composition comprising an orally active opioid agonist and naltrexone, classified in class 514, subclasses 282, 289 and 810.


In response, Applicants hereby elect, without traverse, Group II, claims 12-23, drawn to an oral dosage form composition comprising an orally active opioid agonist and naltrexone, classified in class 514, subclasses 282, 289 and 810.

Applicants respectfully submit that claims 12-23 are pending. Claims 1-3 and 5-9 have been cancelled without prejudice, as they are part of non-elected Group I. Claims 4 and 10-11 were previously canceled.

An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:


Robert J. Paradiso

Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th floor
New York, New York 10018
(212) 736-1940